What is Lexapro Antidepressant?
Escitalopram Oxalate (known also as Lexapro, Cipralex) is an orally administered antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It has been approved for the treatment of advanced depressive disorder and anxiety; it may also be used for social anxiety disorder, panic disorder or obsessive-compulsive disorder.
Lexapro affects chemicals existing in your brain that can turn unbalanced and cause depression or anxiety.
Lexapro (Escitalopram) is at your disposal as tablets and as an oral solution.
Lexapro tablets are film-coated, round, containing escitalopram in strengths equivalent to 5-10-20 mg escitalopram base.
The 10 mg and the 20 mg tablets are marked. The tablets also includes the following actionless ingredients: talc, microcrystalline cellulose/colloidal silicon dioxide, croscarmellose sodium and magnesium stearate. The film coating includes hypromellose, polyethylene glycol, and titanium dioxide.
The oral solution contains escitalopram oxalate of the same value as 1 mg/mL escitalopram base. It also includes the following actionless ingredients: sorbitol, citric acid, purified water, malic acid, sodium citrate, glycerin, methylparaben, propylene glycol, propylparaben, natural peppermint flavor.
A short history of Lexapro Antidepressant
Escitalopram oxalate (or Lexapro) was extended in a close participation between Forest Laboratories and Lundbeck. Its extension was initiated in 1997, and the resulting drug application was entrusted in March 2001, to the U.S. Food and Drug Administration (FDA).
It tooked short time (3.5 years), to develop escitalopram. This can be because of the previous extensive experience with citalopram, of Lundbeck and Forest, which the same pharmacology.
The FDA liberate the approval of escitalopram(Lexapro) for major depression in the summer of 2002 and for anxiety disorder in December 2003.
Escitalopram oxalate can be considered a sample of “evergreening” – the strategy pharmaceutical companies are using in order to increase the lifetime of a drug – of the citalopram franchise in this case.
In 2006, on May 23, the FDA allowed a generic version of escitalopram oxalate by Teva. On July 14 of the same year, the U.S. District Court of Delaware declared in favor of Lundbeck concerning the patent violation dispute and decided the patent on Escitalopram Oxalate valid.
In that year (2006) Forest Laboratories was confered an 2 years and 3 months extension on its patent for Escitalopram Oxalate. This gave a push to the patent expiry from 7th December 2009 to March 14, 2012.